Translation of new technologies: from basic research to drug discovery and development

Area of Science:

• Biotechnology
• Pharmacology
• Genomics

Background:

• High attrition rates in drug discovery, with ~90% of candidates failing in clinical trials.
• Efficacy and toxicity issues, often undetected in preclinical studies, cause significant drug development failures.
• The pharmaceutical industry is adopting multidisciplinary approaches to address these challenges.

Purpose of the Study:

• To explore novel technologies for reducing drug attrition rates.
• To examine the integration of advanced platforms in early-stage drug development.
• To assess the impact of these approaches on clinical trial design.

Main Methods:

• Genomics and related disciplines for understanding disease mechanisms.
• Engineered cell-based and microfluidic systems for predictive toxicology.
• In silico platforms for pharmacokinetic and toxicity assessments.
• Integration of systems biology data with traditional animal-based studies.

Main Results:

• Emerging technologies offer potential to improve prediction of drug efficacy and toxicity.
• Combining diverse data streams enhances the understanding of drug behavior.
• These integrated approaches can refine preclinical safety and pharmacological evaluations.

Conclusions:

• Advanced technologies are crucial for mitigating drug development risks.
• Systems biology approaches integrated with traditional methods can optimize drug discovery pipelines.
• Improved preclinical data can lead to more efficient and successful clinical trial designs.